Form D · Other
TNG Pharmaceuticals, Inc.
Louisville, KY · CIK 0001583185
Offering snapshot reported Aug 5, 2013 · SEC filing
- Reported sold
- $2.64M Offering amount: $4.5M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 2, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 5, 2013 | Initial | $2,644,346 | No comparison | 22 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-200715
Source: Form D, filed Aug 5, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jennifer Corbin | Director, Executive |
| Larry Horn | Director, Executive |
| Serge Martinod | Executive |
| Butch Mercer | Director |
| Kent Van Kampen | Director |
| Phoebe Wood | Director |
Issuer details
Industry: Other (See others in industry)
Address:
201 E Jefferson Street Suite 201
Louisville, KY, 40202
Louisville, KY, 40202